These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3931664)

  • 1. Leuprolide: a review of its effects in animals and man.
    Drago JR; Rohner T; Santen R; Manni A; Lipton A; Harvey H; English H
    Br J Clin Pract Suppl; 1985 Mar; 37():4-7, 16-9. PubMed ID: 3931664
    [No Abstract]   [Full Text] [Related]  

  • 2. Leuprolide: a review of its effects in animals and man.
    Drago JR; Rohner T; Santen R; Manni A; English H; Lipton A; Harvey H
    Br J Clin Pract; 1985 Feb; 39(2):77-9. PubMed ID: 3921048
    [No Abstract]   [Full Text] [Related]  

  • 3. The treatment of prostatic cancer by LH-RH agonist.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetsu I
    Prog Clin Biol Res; 1987; 243A():429-34. PubMed ID: 3116552
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate.
    Garnick MB; Glode LM; Smith JA; Max DT
    Br J Clin Pract Suppl; 1985 Mar; 37():8-12, 20-4. PubMed ID: 3931665
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
    Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
    Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LHRH analogues in the treatment of prostatic cancer. Introduction.
    Dufour B
    Br J Clin Pract Suppl; 1985 Mar; 37():2-3, 14-5. PubMed ID: 3931663
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hypercalcemia: a finding indicative of a prostatic adenocarcinoma].
    Llarena Ibarguren R; Acha Pérez M; Zabala Egurrola JA; Pertusa Peña C
    Actas Urol Esp; 1989; 13(5):409-10. PubMed ID: 2531967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal therapy for prostate cancer.
    Torti FM
    N Engl J Med; 1984 Nov; 311(20):1313-4. PubMed ID: 6436701
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase III studies in prostatic cancer with leuprolide acetate.
    Seely JH
    J Androl; 1987; 8(1):S23-6. PubMed ID: 3104263
    [No Abstract]   [Full Text] [Related]  

  • 12. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate.
    Garnick MB; Glode LM; Smith JA; Max DT
    Br J Clin Pract; 1985 Feb; 39(2):73-6. PubMed ID: 3921047
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of the chronic administration of LH-RH agonist on the oral glucose tolerance test in patients with prostatic carcinoma.
    González-Bárcena D; Pérez-Sánchez P; Hernández-Meza AR; Rangel-García N; Graef-Sánchez A; Comaru-Schally AM; Schally AV
    Arch Invest Med (Mex); 1987; 18(4):273-8. PubMed ID: 2969222
    [No Abstract]   [Full Text] [Related]  

  • 14. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.
    Thompson IM; Zeidman EJ; Rodriguez FR
    J Urol; 1990 Dec; 144(6):1479-80. PubMed ID: 2122011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testicular histology following chronic gonadotropin-releasing hormone agonist treatment.
    Rajfer J; Swerdloff RS; Heber DM
    Fertil Steril; 1984 Nov; 42(5):765-71. PubMed ID: 6436070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leuprolide for prostate cancer.
    Med Lett Drugs Ther; 1985 Aug; 27(694):71-2. PubMed ID: 2410765
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate.
    Sharifi R; Lee M; Ojeda L; Ray P; Stobnicki M; Guinan P
    Urology; 1985 Aug; 26(2):117-24. PubMed ID: 3927551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteinizing hormone-releasing hormone (LH-RH) analogs in treatment of prostatic cancer. Clinical perspective.
    Smith JA
    Urology; 1986 Jan; 27(1 Suppl):9-15. PubMed ID: 3079936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue.
    Smith JA
    Prog Clin Biol Res; 1985; 185A():279-85. PubMed ID: 3929267
    [No Abstract]   [Full Text] [Related]  

  • 20. Newer methods of hormonal therapy for prostate cancer.
    Soloway MS
    Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.